10123852Next generation Alzheimer’s disease screening using blood-based Optomics profilingActiveCollaborative R&DInnovate UKAlzheimer's Disease (AD) and other causes of dementia remains one of the most significant challenges in healthcare. The arrival of new drugs means we are entering the therapeutic era for AD, making diagnosis an increasingly important challenge. Despite recent progress in brain scans and blood tests, there is an urgent need for accessible affordable tests to get paients on the right treatment. Addressing this critical issue, iLoF is pioneering an innovative diagnostic tool that promises to reshape the landscape of AD detection and management. iLoF's groundbreaking Optomics technology utilizes photonics and artificial intelligence to analyze blood-based biomarkers swiftly and non-invasively. This approach offers a stark contrast to the status quo by eliminating complex processing steps and reducing the need for invasive procedures. The test's label-free nature and cost-effectiveness aim to dismantle existing diagnostic barriers, making early and accurate AD detection more accessible than ever before. Participating in the Global Alzheimer's Platform Foundation's Bio-Hermes 2 study, will be transformational to iLoF's Optomics platform, enabling iLoF to refine and validate its technology on a large and diverse patient population. iLoF's technology effectively addresses three main hurdles in AD diagnostics: the high cost of testing, invasiveness, and the lack of clear, conclusive results. By minimizing the volume of blood required for testing and reducing the processing time to under a minute, the Optomics platform is poised to democratize AD diagnostics and catalyze the widespread adoption of label-free, blood-based testing across diverse patient populations. Having advanced to a promising stage in its development, the technology has demonstrated a high level of accuracy in distinguishing AD in several studies. The collaboration with the Bio-Hermes 2 study is expected to further validate and enhance the technology, potentially exceeding the current standards for commercial diagnostic tools. iLoF's strategic approach to the market is informed and precise. The aim is to secure a significant portion of the AD clinical trial market, offering marked cost savings and operational efficiencies in patient screening and trial management. This thoughtful commercial trajectory paves the way for the widespread adoption of this groundbreaking technology. The Optomics platform is not simply an improvement over existing methods but represents a significant leap forward in the fight against Alzheimer's Disease. With the potential to provide rapid, reliable, and accessible diagnostics, iLoF is setting a new benchmark in the healthcare industry, promising enhanced patient outcomes and the acceleration of therapeutic advancements.